Showing results (251-260 of 308) with videos related to

Sort By:
Pageof 31
Cell|July 29, 2006
FOXP3 controls regulatory T cell function through cooperation with NFATYongqing Wu, Madhuri Borde, Vigo Heissmeyer, et al.
The New England Journal of Medicine|August 5, 2011
Lebrikizumab treatment in adults with asthmaJonathan Corren, Robert F Lemanske, Nicola A Hanania, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 24, 2023
Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)Ian D Pavord, Flavia C L Hoyte, Andrew W Lindsley, et al.
Nature|March 28, 2008
TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat functionLiang Zhou, Jared E Lopes, Mark M W Chong, et al.
ERJ Open Research|February 4, 2020
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthmaMario Castro, Klaus F Rabe, Jonathan Corren, et al.
American Journal of Respiratory and Critical Care Medicine|May 22, 2023
Distinct Epithelial-Innate Immune Cell Transcriptional Circuits Underlie Airway Hyperresponsiveness in AsthmaRyan C Murphy, Ying Lai, Matthew Liu, et al.
The Journal of Clinical Investigation|June 3, 2006
Defective regulatory and effector T cell functions in patients with FOXP3 mutationsRosa Bacchetta, Laura Passerini, Eleonora Gambineri, et al.
American Journal of Respiratory Cell and Molecular Biology|May 6, 2026
Infants who develop BPD have an airway endotype defined by vimentin expression and ciliary lossLaurie C Eldredge, Yan Han, Gail H Deutsch, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Infants who develop BPD have an airway endotype defined by vimentin expression and ciliary lossLaurie C Eldredge, Yan Han, Gail H Deutsch, et al.
Lancet (London, England)|May 1, 2016
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialSally Wenzel, Mario Castro, Jonathan Corren, et al.
Pageof 31